Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.

Lundgren C, Bendahl PO, Borg Å, Ehinger A, Hegardt C, Larsson C, Loman N, Malmberg M, Olofsson H, Saal LH, Sjöblom T, Lindman H, Klintman M, Häkkinen J, Vallon-Christersson J, Fernö M, Rydén L, Ekholm M.

Breast Cancer Res Treat. 2019 Nov;178(2):459-467. doi: 10.1007/s10549-019-05378-7. Epub 2019 Aug 20.

PMID:
31432367
2.

Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort.

Dihge L, Vallon-Christersson J, Hegardt C, Saal LH, Häkkinen J, Larsson C, Ehinger A, Loman N, Malmberg M, Bendahl PO, Borg Å, Staaf J, Rydén L.

Clin Cancer Res. 2019 Jul 24. doi: 10.1158/1078-0432.CCR-19-0075. [Epub ahead of print]

PMID:
31340938
3.

Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).

Gezelius E, Bendahl PO, Gonçalves de Oliveira K, Ek L, Bergman B, Sundberg J, Strandberg K, Krämer R, Belting M.

Eur J Cancer. 2019 Sep;118:82-90. doi: 10.1016/j.ejca.2019.06.015. Epub 2019 Jul 18.

4.

Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.

Isaksson S, George AM, Jönsson M, Cirenajwis H, Jönsson P, Bendahl PO, Brunnström H, Staaf J, Saal LH, Planck M.

Acta Oncol. 2019 Aug;58(8):1079-1086. doi: 10.1080/0284186X.2019.1610573. Epub 2019 Jun 24.

PMID:
31230502
5.

Artificial neural network models to predict nodal status in clinically node-negative breast cancer.

Dihge L, Ohlsson M, Edén P, Bendahl PO, Rydén L.

BMC Cancer. 2019 Jun 21;19(1):610. doi: 10.1186/s12885-019-5827-6.

6.

Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.

Sörenby A, Baseckas G, Bendahl PO, Brändstedt J, Håkansson U, Nilsson S, Patschan O, Tinzl M, Wokander M, Liedberg F, Gudjonsson S.

Scand J Urol. 2019 Apr - Jun;53(2-3):109-115. doi: 10.1080/21681805.2019.1604568. Epub 2019 May 8.

PMID:
31064253
7.

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.

Narbe U, Sjöström M, Forsare C, Bendahl PO, Alkner S, Leeb-Lundberg LMF, Lövgren K, Rydén L, Ingvar C, Fernö M.

Breast Cancer Res Treat. 2019 Jun;175(2):305-316. doi: 10.1007/s10549-019-05138-7. Epub 2019 Feb 22.

8.

Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.

Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L; South Swedish and South-East Swedish Breast Cancer Groups.

Eur J Cancer. 2019 Mar;110:53-61. doi: 10.1016/j.ejca.2018.12.034. Epub 2019 Feb 12.

9.

Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer.

Hagman H, Bendahl PO, Lidfeldt J, Belting M, Johnsson A.

PLoS One. 2018 Dec 28;13(12):e0209838. doi: 10.1371/journal.pone.0209838. eCollection 2018.

10.

Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.

Forsare C, Bak M, Falck AK, Grabau D, Killander F, Malmström P, Rydén L, Stål O, Sundqvist M, Bendahl PO, Fernö M.

BMC Cancer. 2018 Dec 7;18(1):1226. doi: 10.1186/s12885-018-5123-x.

11.

Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.

Gezelius E, Flou Kristensen A, Bendahl PO, Hisada Y, Risom Kristensen S, Ek L, Bergman B, Wallberg M, Falkmer U, Mackman N, Pedersen S, Belting M.

PLoS One. 2018 Nov 9;13(11):e0207387. doi: 10.1371/journal.pone.0207387. eCollection 2018.

12.

Stability of oestrogen and progesterone receptor antigenicity in formalin-fixed paraffin-embedded breast cancer tissue over time.

Ehinger A, Bendahl PO, Rydén L, Fernö M, Alkner S.

APMIS. 2018 Sep;126(9):746-754. doi: 10.1111/apm.12884.

PMID:
30160021
13.

Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.

Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer Jörgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K, Rydén L.

Breast Cancer Res. 2018 Jun 8;20(1):48. doi: 10.1186/s13058-018-0976-0.

14.

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.

Jansson S, Aaltonen K, Bendahl PO, Falck AK, Karlsson M, Pietras K, Rydén L.

Breast Cancer Res Treat. 2018 Jun;169(2):231-241. doi: 10.1007/s10549-018-4664-7. Epub 2018 Jan 29.

15.

Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial.

Ek L, Gezelius E, Bergman B, Bendahl PO, Anderson H, Sundberg J, Wallberg M, Falkmer U, Verma S, Belting M; Swedish Lung Cancer Study Group (SLUSG).

Ann Oncol. 2018 Feb 1;29(2):398-404. doi: 10.1093/annonc/mdx716.

16.

CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma.

Isaksson S, Jönsson P, Monsef N, Brunnström H, Bendahl PO, Jönsson M, Staaf J, Planck M.

PLoS One. 2017 Oct 19;12(10):e0186284. doi: 10.1371/journal.pone.0186284. eCollection 2017.

17.

Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.

Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, Saracco A, Hellström M, Veerla S, Paquet E, Bendahl PO, Fernö M, Bergh J, Loman N, Hatschek T, Hedenfalk I; PROMIX Trialists Group.

Int J Cancer. 2018 Feb 1;142(3):618-628. doi: 10.1002/ijc.31070. Epub 2017 Oct 13.

18.

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.

Alkner S, Jensen MB, Rasmussen BB, Bendahl PO, Fernö M, Rydén L, Mouridsen H; Danish Breast Cancer Cooperative Group.

Breast Cancer Res Treat. 2017 Nov;166(2):481-490. doi: 10.1007/s10549-017-4416-0. Epub 2017 Aug 1.

19.

Nomograms for preoperative prediction of axillary nodal status in breast cancer.

Dihge L, Bendahl PO, Rydén L.

Br J Surg. 2017 Oct;104(11):1494-1505. doi: 10.1002/bjs.10583. Epub 2017 Jul 18.

20.

Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.

Elebro K, Bendahl PO, Jernström H, Borgquist S.

Breast Cancer Res Treat. 2017 Oct;165(3):645-657. doi: 10.1007/s10549-017-4343-0. Epub 2017 Jun 22.

21.

Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.

Aaltonen KE, Novosadová V, Bendahl PO, Graffman C, Larsson AM, Rydén L.

Oncotarget. 2017 Jul 11;8(28):45544-45565. doi: 10.18632/oncotarget.17271.

22.

Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.

Kimbung S, Chang CY, Bendahl PO, Dubois L, Thompson JW, McDonnell DP, Borgquist S.

Endocr Relat Cancer. 2017 Jul;24(7):339-349. doi: 10.1530/ERC-16-0533. Epub 2017 Apr 25.

23.

Long-term third-party assessment of results after continent cutaneous diversion with Lundiana pouch.

Liedberg F, Gudjonsson S, Xu A, Bendahl PO, Davidsson T, Månsson W.

BJU Int. 2017 Oct;120(4):530-536. doi: 10.1111/bju.13863. Epub 2017 Apr 19.

24.

Vasoactive peptides associate with treatment outcome ofbevacizumab-containing therapy in metastatic colorectal cancer.

Hagman H, Bendahl PO, Melander O, Sundberg J, Johnsson A, Belting M.

Acta Oncol. 2017 May;56(5):653-660. doi: 10.1080/0284186X.2017.1302098. Epub 2017 Mar 17.

PMID:
28303751
25.

Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis.

Evans CE, Palazon A, Sim J, Tyrakis PA, Prodger A, Lu X, Chan S, Bendahl PO, Belting M, Von Euler L, Rundqvist H, Johnson RS, Branco C.

Biol Open. 2017 May 15;6(5):688-697. doi: 10.1242/bio.024653.

26.

Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.

Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, Grabau D, Rydén L, Stål O, Fernö M; South and South-East Swedish Breast Cancer Groups.

Acta Oncol. 2017 Jan;56(1):68-74. doi: 10.1080/0284186X.2016.1237778. Epub 2016 Oct 20.

PMID:
27762648
27.
28.

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.

Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L.

J Clin Oncol. 2016 Jul 1;34(19):2232-8. doi: 10.1200/JCO.2015.65.6272. Epub 2016 May 9.

29.

The accuracy of preoperative axillary nodal staging in primary breast cancer by ultrasound is modified by nodal metastatic load and tumor biology.

Dihge L, Grabau DA, Rasmussen RW, Bendahl PO, Rydén L.

Acta Oncol. 2016 Aug;55(8):976-82. doi: 10.3109/0284186X.2016.1146826. Epub 2016 Apr 6.

30.

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.

Alkner S, Bendahl PO, Ehinger A, Lövgren K, Rydén L, Fernö M.

PLoS One. 2016 Mar 9;11(3):e0150977. doi: 10.1371/journal.pone.0150977. eCollection 2016.

31.

An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.

Holm K, Staaf J, Lauss M, Aine M, Lindgren D, Bendahl PO, Vallon-Christersson J, Barkardottir RB, Höglund M, Borg Å, Jönsson G, Ringnér M.

Breast Cancer Res. 2016 Feb 29;18(1):27. doi: 10.1186/s13058-016-0685-5.

32.

St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.

Falck AK, Röme A, Fernö M, Olsson H, Chebil G, Bendahl PO, Rydén L.

Br J Surg. 2016 Apr;103(5):513-23. doi: 10.1002/bjs.10070. Epub 2016 Feb 9.

33.

Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation.

Evans CE, Bendahl PO, Belting M, Branco C, Johnson RS.

Blood. 2016 Mar 10;127(10):1355-60. doi: 10.1182/blood-2015-09-671982. Epub 2015 Dec 23.

34.

Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer.

Olsson E, Winter C, George A, Chen Y, Törngren T, Bendahl PO, Borg Å, Gruvberger-Saal SK, Saal LH.

PLoS One. 2015 Dec 15;10(12):e0144528. doi: 10.1371/journal.pone.0144528. eCollection 2015.

35.

Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing.

Tang MH, Dahlgren M, Brueffer C, Tjitrowirjo T, Winter C, Chen Y, Olsson E, Wang K, Törngren T, Sjöström M, Grabau D, Bendahl PO, Rydén L, Niméus E, Saal LH, Borg Å, Gruvberger-Saal SK.

Oncotarget. 2015 Nov 10;6(35):37169-84. doi: 10.18632/oncotarget.5951.

36.

Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.

Kimbung S, Kovács A, Danielsson A, Bendahl PO, Lövgren K, Frostvik Stolt M, Tobin NP, Lindström L, Bergh J, Einbeigi Z, Fernö M, Hatschek T, Hedenfalk I.

Oncotarget. 2015 Oct 20;6(32):33306-18. doi: 10.18632/oncotarget.5089.

37.

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model.

Elgström E, Eriksson SE, Ljungberg O, Bendahl PO, Ohlsson TG, Nilsson R, Tennvall J.

EJNMMI Res. 2015 Dec;5(1):47. doi: 10.1186/s13550-015-0126-y. Epub 2015 Sep 15.

38.

Protease Activated Receptors 1 and 2 Correlate Differently with Breast Cancer Aggressiveness Depending on Tumor ER Status.

Lidfeldt J, Bendahl PO, Forsare C, Malmström P, Fernö M, Belting M.

PLoS One. 2015 Aug 5;10(8):e0134932. doi: 10.1371/journal.pone.0134932. eCollection 2015.

39.

Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.

Alkner S, Ehinger A, Bendahl PO, Rydén L, Fernö M.

Eur J Cancer. 2015 Nov;51(16):2304-13. doi: 10.1016/j.ejca.2015.07.016. Epub 2015 Aug 1.

PMID:
26243193
40.

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D, van Westen D, Fernö M, Ingvar C, Rose C, Bendahl PO, Rydén L, Borg Å, Gruvberger-Saal SK, Jernström H, Saal LH.

EMBO Mol Med. 2015 Aug;7(8):1034-47. doi: 10.15252/emmm.201404913.

41.

Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.

Ekholm M, Grabau D, Bendahl PO, Bergh J, Elmberger G, Olsson H, Russo L, Viale G, Fernö M.

Acta Oncol. 2015 Jul;54(7):1040-8. doi: 10.3109/0284186X.2015.1037012. Epub 2015 May 11.

PMID:
25959664
42.

Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.

Feldt M, Bjarnadottir O, Kimbung S, Jirström K, Bendahl PO, Veerla S, Grabau D, Hedenfalk I, Borgquist S.

J Transl Med. 2015 Apr 29;13:133. doi: 10.1186/s12967-015-0486-0.

43.

Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.

Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, Rosengren F, Werner-Hartman L, Törngren T, Kvist A, Fredlund E, Bendahl PO, Jirström K, Lundgren L, Howlin J, Borg Å, Gruvberger-Saal SK, Saal LH, Nielsen K, Ringnér M, Tsao H, Olsson H, Ingvar C, Staaf J, Jönsson G.

Oncotarget. 2015 May 20;6(14):12297-309.

44.

Global Transcriptional Changes Following Statin Treatment in Breast Cancer.

Bjarnadottir O, Kimbung S, Johansson I, Veerla S, Jönsson M, Bendahl PO, Grabau D, Hedenfalk I, Borgquist S.

Clin Cancer Res. 2015 Aug 1;21(15):3402-11. doi: 10.1158/1078-0432.CCR-14-1403. Epub 2015 Apr 3.

45.

The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.

Jansson S, Bendahl PO, Grabau DA, Falck AK, Fernö M, Aaltonen K, Rydén L.

PLoS One. 2014 Jul 15;9(7):e102176. doi: 10.1371/journal.pone.0102176. eCollection 2014.

46.

A novel model for Ki67 assessment in breast cancer.

Romero Q, Bendahl PO, Fernö M, Grabau D, Borgquist S.

Diagn Pathol. 2014 Jun 16;9:118. doi: 10.1186/1746-1596-9-118.

47.

Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events.

Simonsson M, Markkula A, Bendahl PO, Rose C, Ingvar C, Jernström H.

Springerplus. 2014 May 22;3:261. doi: 10.1186/2193-1801-3-261. eCollection 2014.

48.

Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor.

Narbe U, Bendahl PO, Grabau D, Rydén L, Ingvar C, Fernö M.

Springerplus. 2014 Feb 6;3:70. doi: 10.1186/2193-1801-3-70. eCollection 2014.

49.

Efficient and reproducible identification of mismatch repair deficient colon cancer: validation of the MMR index and comparison with other predictive models.

Joost P, Bendahl PO, Halvarsson B, Rambech E, Nilbert M.

BMC Clin Pathol. 2013 Dec 17;13(1):33. doi: 10.1186/1472-6890-13-33.

50.

The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.

Klintman M, Strand C, Ahlin C, Beglerbegovic S, Fjällskog ML, Grabau D, Gudlaugsson E, Janssen EA, Lövgren K, Skaland I, Bendahl PO, Malmström P, Baak JP, Fernö M.

PLoS One. 2013 Dec 4;8(12):e81902. doi: 10.1371/journal.pone.0081902. eCollection 2013.

Supplemental Content

Loading ...
Support Center